{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:46:03Z","timestamp":1759063563796},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Janssen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2444-3","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T13:41:09Z","timestamp":1496410869000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Simeprevir with peginterferon \u03b1-2a\/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study"],"prefix":"10.1186","volume":"17","author":[{"given":"Edward J.","family":"Gane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin","family":"DeJesus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Janczewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moises","family":"Diago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariliza Hendrique","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henk","family":"Reesink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Nikitin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Hinrichsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ferenci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umesh","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Kalmeijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Fevery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Corbett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Beumont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Jessner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,2]]},"reference":[{"key":"2444_CR1","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gon\u00e7ales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975\u201382.","journal-title":"N Engl J Med"},{"key":"2444_CR2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","volume":"376","author":"PY Kwo","year":"2010","unstructured":"Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376:705\u201316.","journal-title":"Lancet"},{"key":"2444_CR3","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","volume":"362","author":"JG McHutchison","year":"2010","unstructured":"McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292\u2013303.","journal-title":"N Engl J Med"},{"key":"2444_CR4","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1002\/hep.1840360730","volume":"36","author":"MW Fried","year":"2002","unstructured":"Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36:S237\u201344.","journal-title":"Hepatology"},{"key":"2444_CR5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrgastro.2011.21","volume":"8","author":"MS Sulkowski","year":"2011","unstructured":"Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8:212\u201323.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2444_CR6","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/hep.26641","volume":"58","author":"MW Fried","year":"2013","unstructured":"Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-na\u00eeve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58:1918\u201329.","journal-title":"Hepatology"},{"key":"2444_CR7","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jhep.2011.12.033","volume":"56","author":"C Moreno","year":"2012","unstructured":"Moreno C, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem S, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol. 2012;56:1247\u201353.","journal-title":"J Hepatol"},{"key":"2444_CR8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1053\/j.gastro.2009.10.033","volume":"138","author":"HW Reesink","year":"2010","unstructured":"Reesink HW, Fanning GC, Farha KA. Weegink C, Van Vliet A, van 't Klooster G, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology. 2010;138:913\u201321.","journal-title":"Gastroenterology"},{"key":"2444_CR9","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2013.10.058","volume":"146","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology. 2014;146:430\u201341.","journal-title":"Gastroenterology"},{"key":"2444_CR10","unstructured":"Janssen-Cilag International NV. Olysio 150 mg hard capsules. Summary of Product Characteristics. 2017. \nhttp:\/\/www.medicines.org.uk\/emc\/medicine\/28888#PHARMACOKINETIC_PROPS\n\n. Accessed 19 May 2017."},{"key":"2444_CR11","unstructured":"Janssen Research & Development. Olysio\u2122 (simeprevir) US Prescribing Information 2017. \nhttp:\/\/www.olysio.com\/shared\/product\/olysio\/prescribing-information.pdf\n\n. Accessed 19 May 2017."},{"key":"2444_CR12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","volume":"384","author":"IM Jacobson","year":"2014","unstructured":"Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384:403\u201313.","journal-title":"Lancet"},{"key":"2444_CR13","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384:414\u201326.","journal-title":"Lancet"},{"key":"2444_CR14","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","volume":"146","author":"X Forns","year":"2014","unstructured":"Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146:1669\u201379.","journal-title":"Gastroenterology"},{"key":"2444_CR15","doi-asserted-by":"crossref","unstructured":"Bourgeois S, Reesink HW, Leempoels J, Vijgen L, Rouan MC, Marien K, et al. Combination therapy of TMC647055 with simeprevir (TMC435) in chronic hepatitis C patients [abstract]. J Hepatol. 2013;58:S483.","DOI":"10.1016\/S0168-8278(13)61189-7"},{"key":"2444_CR16","unstructured":"World Health Organization. WHO toxicity grading scale for determining the severity of adverse events 2003. \nhttp:\/\/www.icssc.org\/documents\/resources\/aemanual2003appendicesfebruary_06_2003%20final.pdf\n\n. Accessed 20 Feb 2017."},{"key":"2444_CR17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(14)71002-3","volume":"15","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, Zeuzem S, Zoulim F, Weiland O, Horban A, Stanciu C, et al. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect Dis. 2015;15:27\u201335.","journal-title":"Lancet Infect Dis"},{"key":"2444_CR18","unstructured":"American Association for the Study of Liver Diseases. Recommendations for testing, managing, and treating Hepatitis C 2017. \nwww.hcvguidelines.org\/full-report-view\n\n. Accessed 19 May 2017."},{"key":"2444_CR19","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2014.11.032","volume":"62","author":"O Lenz","year":"2015","unstructured":"Lenz O, Verbinnen T, Fevery B, Tambuyzer L, Vijgen L, Peeters M, et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in Phase IIb\/III studies. J Hepatol. 2015;62:1008\u201314.","journal-title":"J Hepatol"},{"key":"2444_CR20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153\u201394.","journal-title":"J Hepatol"},{"key":"2444_CR21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399\u2013401.","journal-title":"Nature"},{"key":"2444_CR22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","volume":"139","author":"AJ Thompson","year":"2010","unstructured":"Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120\u20139.","journal-title":"Gastroenterology"},{"key":"2444_CR23","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1365-2036.2011.04716.x","volume":"34","author":"M Eslam","year":"2011","unstructured":"Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther. 2011;34:297\u2013305.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2444-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T13:41:27Z","timestamp":1496410887000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2444-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,2]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2444"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2444-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,2]]},"article-number":"389"}}